The Role of Leukotriene B4 in Allergic Diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Leukotriene B(4) (LTB(4)) is a lipid mediator with potent chemoattractant properties and that is rapidly generated from activated innate immune cells such as neutrophils, macrophages, and mast cells. Elevated levels of LTB(4) have been reported in various allergic diseases and these levels have been related to disease activity and response to treatment. Recent studies using LTB(4) receptor-1 (BLT1) antagonists or BLT1-deficient mice have revealed that ligation of BLT1 by LTB(4) is important for the activation and recruitment of inflammatory cells including neutrophils, eosinophils, monocytes/macrophages, mast cells, dendritic cells, and more recently, effector T cells to inflamed tissues in various inflammatory diseases. The LTB(4)/BLT1 pathway appears to play an important role in the pathogenesis of severe persistent asthma, aspirin- and exercise-induced asthma, allergic rhinitis, and atopic dermatitis together with other mediators including cysteinyl leukotrienes, cytokines, and chemokines. LTB(4) production is in general resistant to corticosteroid treatment. In fact, corticosteroids can upregulate BLT1 expression on corticosteroid-resistant inflammatory cells such as neutrophils, monocytes, and effector memory CD8+ T cells. As a result, this corticosteroid-resistant LTB(4)/BLT1 pathway may contribute to the development of inflammation in allergic diseases that do not respond to the introduction of corticosteroids. Inhibition of this pathway has potential therapeutic benefit in various allergic diseases that have involvement of corticosteroid-insensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Cited by
Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease
Yates, C. M., Calder, P. C., & Ed Rainger, G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.010 · Cited by 395
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174
Moreira, A. P., & Hogaboam, C. M. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0027 · Cited by 139
Role of innate immunity in the pathogenesis of allergic rhinitis
Melvin, T.-A. N., & Ramanathan, M. (2012) · Current Opinion in Otolaryngology & Head and Neck Surgery · doi:10.1097/moo.0b013e3283533632 · Cited by 42
“One possibility for this ineffectiveness was demonstrated in a study examining leukotriene B(4) [LTB(4)], a potent lipid mediator that is rapidly generated from activated innate immune cells [33].”
Background
Metadata
- Authors
- Ohnishi, H., Miyahara, N., & Gelfand, E. W.
- Venue
- Allergology International
- Publisher
- Japanese Society of Allergology
- Published
- 2008
- Volume
- 57
- Issue
- 4
- Pages
- 291-298
- ISSN
- 1323-8930 (ISSN-L)
- OpenAlex
- W2070550392
- Cited by
- 121
- References
- 1
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Leukotriene B4 in Allergic Diseases. https://app.cochat.ai/papers/10.2332/allergolint.08-rai-0019
- The paper
- Ohnishi, H., Miyahara, N., & Gelfand, E. W. (2008). The Role of Leukotriene B4 in Allergic Diseases. Allergology International. https://doi.org/10.2332/allergolint.08-rai-0019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.